PMID- 26604914
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151125
LR  - 20220311
IS  - 1673-5374 (Print)
IS  - 1876-7958 (Electronic)
IS  - 1673-5374 (Linking)
VI  - 10
IP  - 9
DP  - 2015 Sep
TI  - Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve 
      diseases: a case report of improvement in relapsing auto-immune optic neuropathy.
PG  - 1507-15
LID - 10.4103/1673-5374.165525 [doi]
AB  - We present the results from a patient with relapsing optic neuropathy treated 
      within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an 
      Institutional Review Board approved clinical trial and has become the largest 
      ophthalmology stem cell study registered at the National Institutes of Health to 
      date (www.clinicaltrials.gov Identifier NCT 01920867). SCOTS utilizes autologous 
      bone marrow-derived stem cells (BMSCs) for treatment of retinal and optic nerve 
      diseases. Pre-treatment and post-treatment comprehensive eye exams of a 54 year 
      old female patient were performed both at the Florida Study Center, USA and at 
      The Eye Center of Columbus, USA. As a consequence of a relapsing optic neuritis, 
      the patient's previously normal visual acuity decreased to between 20/350 and 
      20/400 in the right eye and to 20/70 in the left eye. Significant visual field 
      loss developed bilaterally. The patient underwent a right eye vitrectomy with 
      injection of BMSCs into the optic nerve of the right eyeand retrobulbar, subtenon 
      and intravitreal injection of BMSCs in the left eye. At 15 months after SCOTS 
      treatment, the patient's visual acuity had improved to 20/150 in the right eye 
      and 20/20 in the left eye. Bilateral visual fields improved markedly. Both 
      macular thickness and fast retinal nerve fiber layer thickness were maximally 
      improved at 3 and 6 months after SCOTS treatment. The patient also reduced her 
      mycophenylate dose from 1,500 mg per day to 500 mg per day and required no 
      steroid pulse therapy during the 15-month follow up.
FAU - Weiss, Jeffrey N
AU  - Weiss JN
AD  - Retina Associates of South Florida, Margate, FL, USA.
FAU - Levy, Steven
AU  - Levy S
AUID- ORCID: 0000-0002-9313-3448
AD  - MD Stem Cells, Ridgefield, CT, USA.
FAU - Benes, Susan C
AU  - Benes SC
AD  - Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC4625519
OTO - NOTNLM
OT  - Stem Cell Ophthalmology Treatment Study
OT  - autoimmune
OT  - blindness
OT  - bone marrow-derived stem cells
OT  - nerve regeneration
OT  - neural regeneration
OT  - ophthalmology
OT  - optic nerve
OT  - optic neuropathy
OT  - stem cells
OT  - visual loss
COIS- Conflicts of interest: None declared.
EDAT- 2015/11/26 06:00
MHDA- 2015/11/26 06:01
PMCR- 2015/09/01
CRDT- 2015/11/26 06:00
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2015/11/26 06:01 [medline]
PHST- 2015/09/01 00:00 [pmc-release]
AID - NRR-10-1507 [pii]
AID - 10.4103/1673-5374.165525 [doi]
PST - ppublish
SO  - Neural Regen Res. 2015 Sep;10(9):1507-15. doi: 10.4103/1673-5374.165525.